Clinical Trial Update: Anti-CD20 Antibodies for Treatment of SLE-PAH [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating anti-CD20 antibodies for treatment of systemic lupus erythematosus-associated pulmonary arterial hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension
• Systemic Lupus Erythematosus

Drugs mentioned

• anti-CD20 antibodies

Snippet

Sponsor: Chinese SLE Treatment And Research Group | Conditions: Systemic Lupus Erythematosus, Pulmonary Arterial Hypertension | Phase 4 | Status: UNKNOWN